General MedicationsINJECTIONStandard
BLINCYTO
BLINATUMOMAB
Standard Dose
35MCG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview BLINCYTO is listed in Drugs@FDA under application 125557 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient BLINATUMOMAB Form and strength INJECTABLE;INJECTION - 35MCG Sponsor AMGEN Submission history Latest submission status date: 2025-10-21 00:00:00.
Structured Monograph
Clinical summary
Approval overview BLINCYTO is listed in Drugs@FDA under application 125557 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient BLINATUMOMAB Form and strength INJECTABLE;INJECTION - 35MCG Sponsor AMGEN Submission history Latest submission status date: 2025-10-21 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.